Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?

[1]  J. Edmonson.  Needed: qualitative improvement in antisarcoma therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Kvols,et al.  Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? , 1994, Journal of the National Cancer Institute.

[3]  J. Edmonson,et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Dorr Rt.  Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor , 1993 .

[5]  D. Blaise,et al.  [Hematopoietic growth factors]. , 1993, Presse medicale.

[6]  R. Dorr.  Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. , 1993, Clinical therapeutics.

[7]  D. Crowther,et al.  Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Hartmann,et al.  Granulocyte‐macrophage colony‐stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin , 1992, Cancer.

[9]  K. Diederichs,et al.  Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. , 1991, Science.

[10]  A. Burgess,et al.  Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity. , 1990, The Journal of biological chemistry.

[11]  D. Gemsa,et al.  Macrophage activation by granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2. , 1989, Journal of immunology.

[12]  T. Whiteside,et al.  Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. , 1989, Blood.

[13]  D. Crowther,et al.  Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. , 1989, British Journal of Cancer.

[14]  E. Vellenga,et al.  Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. , 1988, Blood.

[15]  P. O'Hara,et al.  Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. , 1987, Biochemistry.

[16]  J. Mermod,et al.  Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast or animal cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Liehl,et al.  Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. , 1987, Blood.

[18]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[19]  C. Sieff.  Hematopoietic growth factors. , 1987, The Journal of clinical investigation.

[20]  R. Kaufman,et al.  Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. , 1986, Cold Spring Harbor symposia on quantitative biology.

[21]  D. Golde,et al.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. , 1984, Science.